Eli Lilly Reports Strong Results for GLP-1 Drugs Amidst Competition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: NASDAQ.COM
- Significant Sales Growth: In Q1 2026, Eli Lilly's Mounjaro and Zepbound saw sales increase by 125% and 80% respectively, demonstrating robust performance in the GLP-1 market and reinforcing its leadership position.
- International Market Advantage: Despite the influx of low-cost generics in India, Mounjaro's sales grew by 10%, indicating sustained consumer appeal and potentially laying the groundwork for future international expansion.
- Market Share Increase: Morgan Stanley estimates that Eli Lilly controls over 50% of the international market, driven by Mounjaro's superior weight-loss results, suggesting strong growth potential globally.
- Valuation Considerations: While Eli Lilly's price-to-earnings ratio stands at approximately 38x, down from a five-year average of 56x, it may not attract value investors; however, aggressive growth investors might reassess its long-term opportunities in the international market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1082.920
Low
950.00
Averages
1192
High
1500
Current: 1082.920
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Expands Coverage for Obesity Medications
- Expanded Coverage: Eli Lilly announced that its obesity medication portfolio will be covered by the three largest pharmacy benefit managers in the U.S., significantly increasing access to FDA-approved treatment options for millions of Americans, thereby enhancing patient choice and accessibility.
- Reduced Medication Costs: Starting June 1, eligible patients will pay as little as $25 per month for Foundayo and Zepbound, which is expected to significantly lower the financial burden on patients and promote broader adoption of these medications.
- Clinical Trial Validation: The ATTAIN-1 and ATTAIN-2 clinical trials enrolled over 4,500 individuals with obesity or overweight, demonstrating that Foundayo led to an average weight loss of 27.3 pounds (12.4%) over 72 weeks, providing robust evidence of its efficacy and further solidifying Lilly's market position in obesity treatment.
- Competitive Market Advantage: Zepbound, the most prescribed injectable obesity medication in the U.S., achieved an average weight loss of 15% (34 lbs) over 72 weeks, enhancing patients' quality of life and securing a larger market share for Lilly in the competitive obesity drug landscape.
See More
France Becomes First EU Nation to Reimburse Weight Loss Medications
- Reimbursement Policy: France's Health Minister Stephanie Rist announced that France is the first EU nation to reimburse weight loss medications, specifically for severely obese patients, marking a significant advancement in public health policy.
- Eligibility Criteria: Under the new policy, patients with a body mass index (BMI) of at least 35 with one comorbidity or a BMI of at least 40 will qualify for coverage, potentially benefiting around one million individuals in need.
- Financial Impact Assessment: The initiative is expected to cost approximately €100 million ($116 million) annually at full rollout, imposing a financial burden on French taxpayers while potentially reducing long-term healthcare costs associated with obesity.
- Market Competition Dynamics: With this policy, weight loss medications from Novo Nordisk (NVO) and Eli Lilly (LLY) will gain broader market acceptance in France, which may influence policy decisions in other EU countries and drive overall market growth.
See More
Small Biotech Firms Rapidly Adopt AI for Efficiency
- Accelerated AI Adoption: Tencent's healthcare division head noted that small biotech firms are adopting AI more rapidly than larger companies to enhance efficiency, particularly in R&D, where pharmaceutical firms leverage new modeling tools and automated labs to reduce costs and shorten drug development timelines.
- Collaboration Trend: Pharmaceutical companies, including Novo Nordisk and Eli Lilly, have established AI-related collaborations with tech firms, indicating a strong industry focus on AI technology aimed at improving R&D efficiency through innovation.
- Challenges for Large Firms: While AI is quickly embraced by smaller firms, large pharmaceutical companies face challenges due to their complex organizations and established workflows, suggesting that merely adding AI may not yield successful outcomes in these environments.
- Optimistic Industry Outlook: Industry forecasts suggest that within the next three to five years, using machine learning to optimize target discovery, design molecules, and streamline clinical trial planning could halve early-stage development timelines and costs, highlighting the significant potential of AI in the pharmaceutical sector.
See More
CVS Restores Coverage for Eli Lilly's Weight Loss Drug
- Formulary Update: CVS Caremark announced it will restore coverage for Eli Lilly's weight-loss drug Zepbound effective October 1, which is expected to enhance patient options and improve its competitive position in the market.
- New Drug Addition: CVS Caremark will also add Eli Lilly's new weight-loss pill Foundayo (orforglipron) effective June 1, further enriching its formulary to meet patient demand for weight-loss medications.
- Market Competition Dynamics: Eli Lilly's stock faced pressure after CVS Caremark selected Novo Nordisk's Wegovy as the preferred GLP-1 drug, and the restoration of Zepbound's coverage is likely to alleviate this pressure and enhance its market performance.
- Improving Drug Accessibility: CVS Health stated that these updates are part of its ongoing efforts to address rising prescription drug costs and improve access to affordable medications for millions of Americans, demonstrating the company's commitment to patient needs.
See More
CVS Reintroduces Eli Lilly's Zepbound to Drug Lists
- Drug Coverage Restoration: CVS Health announced the reintroduction of Eli Lilly's weight-loss drug Zepbound to its drug lists, effective October 1, aiming to provide employers and health plans with more affordable GLP-1 weight-loss treatment options, thereby enhancing market competitiveness.
- Competitive Strategy Adjustment: CVS's pharmacy benefit management unit, Caremark, had previously dropped Zepbound from coverage on July 1 last year, but decided to restore it after negotiating a favorable price with rival Novo Nordisk's Wegovy, demonstrating flexibility in drug pricing negotiations.
- New Drug Coverage Policy: CVS will also lift the new-to-market block on Eli Lilly's recently launched oral pill, Foundayo, effective June 1, allowing health plans to cover this medication and further expanding treatment options for patients.
- Market Demand Changes: The increasing popularity and high prices of GLP-1 drugs have led many employers and health plans to limit or drop coverage for weight-loss use, prompting CVS to actively engage in negotiations to improve drug accessibility and affordability for its customers.
See More
CVS Restores Coverage for Eli Lilly's Weight Loss Drug Zepbound
- Coverage Restoration: CVS Health announced it will restore coverage for Eli Lilly's weight loss injection Zepbound on October 1 and will start covering the newly approved obesity pill Foundayo on June 1, providing patients with more treatment options and enhancing Lilly's competitive position in the weight loss drug market.
- Market Competition Balance: This move levels the playing field between Lilly and Novo Nordisk in CVS's major drug plans, especially after CVS's agreement with Novo last year that made Wegovy the preferred obesity treatment, which previously excluded Zepbound and forced patients to incur higher out-of-pocket costs.
- Potential Savings: CVS expects the restoration of coverage to drive an additional 10% to 15% savings across the weight management category, which not only helps patients reduce medication costs but may also stimulate competition in the GLP-1 drug market, facilitating successful pricing negotiations.
- Smooth Transition: CVS Caremark has committed to ensuring a smooth transition for customers, consultants, providers, and members to the newly covered therapies, reflecting CVS's leadership in the market and its proactive efforts to enhance drug affordability.
See More
Eli Lilly Expands Coverage for Obesity Medications
- Expanded Coverage: Eli Lilly announced that its obesity medication portfolio will be covered by the three largest pharmacy benefit managers in the U.S., significantly increasing access to FDA-approved treatment options for millions of Americans, thereby enhancing patient choice and accessibility.
- Reduced Medication Costs: Starting June 1, eligible patients will pay as little as $25 per month for Foundayo and Zepbound, which is expected to significantly lower the financial burden on patients and promote broader adoption of these medications.
- Clinical Trial Validation: The ATTAIN-1 and ATTAIN-2 clinical trials enrolled over 4,500 individuals with obesity or overweight, demonstrating that Foundayo led to an average weight loss of 27.3 pounds (12.4%) over 72 weeks, providing robust evidence of its efficacy and further solidifying Lilly's market position in obesity treatment.
- Competitive Market Advantage: Zepbound, the most prescribed injectable obesity medication in the U.S., achieved an average weight loss of 15% (34 lbs) over 72 weeks, enhancing patients' quality of life and securing a larger market share for Lilly in the competitive obesity drug landscape.
See More
France Becomes First EU Nation to Reimburse Weight Loss Medications
- Reimbursement Policy: France's Health Minister Stephanie Rist announced that France is the first EU nation to reimburse weight loss medications, specifically for severely obese patients, marking a significant advancement in public health policy.
- Eligibility Criteria: Under the new policy, patients with a body mass index (BMI) of at least 35 with one comorbidity or a BMI of at least 40 will qualify for coverage, potentially benefiting around one million individuals in need.
- Financial Impact Assessment: The initiative is expected to cost approximately €100 million ($116 million) annually at full rollout, imposing a financial burden on French taxpayers while potentially reducing long-term healthcare costs associated with obesity.
- Market Competition Dynamics: With this policy, weight loss medications from Novo Nordisk (NVO) and Eli Lilly (LLY) will gain broader market acceptance in France, which may influence policy decisions in other EU countries and drive overall market growth.
See More
Small Biotech Firms Rapidly Adopt AI for Efficiency
- Accelerated AI Adoption: Tencent's healthcare division head noted that small biotech firms are adopting AI more rapidly than larger companies to enhance efficiency, particularly in R&D, where pharmaceutical firms leverage new modeling tools and automated labs to reduce costs and shorten drug development timelines.
- Collaboration Trend: Pharmaceutical companies, including Novo Nordisk and Eli Lilly, have established AI-related collaborations with tech firms, indicating a strong industry focus on AI technology aimed at improving R&D efficiency through innovation.
- Challenges for Large Firms: While AI is quickly embraced by smaller firms, large pharmaceutical companies face challenges due to their complex organizations and established workflows, suggesting that merely adding AI may not yield successful outcomes in these environments.
- Optimistic Industry Outlook: Industry forecasts suggest that within the next three to five years, using machine learning to optimize target discovery, design molecules, and streamline clinical trial planning could halve early-stage development timelines and costs, highlighting the significant potential of AI in the pharmaceutical sector.
See More
CVS Restores Coverage for Eli Lilly's Weight Loss Drug
- Formulary Update: CVS Caremark announced it will restore coverage for Eli Lilly's weight-loss drug Zepbound effective October 1, which is expected to enhance patient options and improve its competitive position in the market.
- New Drug Addition: CVS Caremark will also add Eli Lilly's new weight-loss pill Foundayo (orforglipron) effective June 1, further enriching its formulary to meet patient demand for weight-loss medications.
- Market Competition Dynamics: Eli Lilly's stock faced pressure after CVS Caremark selected Novo Nordisk's Wegovy as the preferred GLP-1 drug, and the restoration of Zepbound's coverage is likely to alleviate this pressure and enhance its market performance.
- Improving Drug Accessibility: CVS Health stated that these updates are part of its ongoing efforts to address rising prescription drug costs and improve access to affordable medications for millions of Americans, demonstrating the company's commitment to patient needs.
See More
CVS Reintroduces Eli Lilly's Zepbound to Drug Lists
- Drug Coverage Restoration: CVS Health announced the reintroduction of Eli Lilly's weight-loss drug Zepbound to its drug lists, effective October 1, aiming to provide employers and health plans with more affordable GLP-1 weight-loss treatment options, thereby enhancing market competitiveness.
- Competitive Strategy Adjustment: CVS's pharmacy benefit management unit, Caremark, had previously dropped Zepbound from coverage on July 1 last year, but decided to restore it after negotiating a favorable price with rival Novo Nordisk's Wegovy, demonstrating flexibility in drug pricing negotiations.
- New Drug Coverage Policy: CVS will also lift the new-to-market block on Eli Lilly's recently launched oral pill, Foundayo, effective June 1, allowing health plans to cover this medication and further expanding treatment options for patients.
- Market Demand Changes: The increasing popularity and high prices of GLP-1 drugs have led many employers and health plans to limit or drop coverage for weight-loss use, prompting CVS to actively engage in negotiations to improve drug accessibility and affordability for its customers.
See More
CVS Restores Coverage for Eli Lilly's Weight Loss Drug Zepbound
- Coverage Restoration: CVS Health announced it will restore coverage for Eli Lilly's weight loss injection Zepbound on October 1 and will start covering the newly approved obesity pill Foundayo on June 1, providing patients with more treatment options and enhancing Lilly's competitive position in the weight loss drug market.
- Market Competition Balance: This move levels the playing field between Lilly and Novo Nordisk in CVS's major drug plans, especially after CVS's agreement with Novo last year that made Wegovy the preferred obesity treatment, which previously excluded Zepbound and forced patients to incur higher out-of-pocket costs.
- Potential Savings: CVS expects the restoration of coverage to drive an additional 10% to 15% savings across the weight management category, which not only helps patients reduce medication costs but may also stimulate competition in the GLP-1 drug market, facilitating successful pricing negotiations.
- Smooth Transition: CVS Caremark has committed to ensuring a smooth transition for customers, consultants, providers, and members to the newly covered therapies, reflecting CVS's leadership in the market and its proactive efforts to enhance drug affordability.
See More
